We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 343

Federal Court of Appeal grants minister of health the right to be wrong
  • Gowling WLG
  • Canada
  • November 30 2016

In an October 12 2016 decision (Teva Canada Limited v Pfizer Canada Inc, 2016 FCA 248) the Federal Court of Appeal upheld two decisions of the


Monetary consequences for falsely alleging patent infringement
  • Gowling WLG
  • Canada
  • November 21 2016

The Federal Court released a decision on Nov. 17, 2016 regarding two patent actions that were heard together.1 The actions were between Advantage


Challenge to patentee’s right to elect between damages and accounting of profits rejected
  • Gowling WLG
  • Canada
  • November 10 2016

Which party has the right to choose the patentee’s remedy after a successful action for patent infringement? In Canada, it has long been the case that


Patents in Canada: Lexology Navigator Q&A
  • Gowling WLG
  • Canada, Global
  • November 1 2016

A structured guide to patents law and practice in Canada


Applications for leave to appeal dismissed - 27 October 2016
  • Gowling WLG
  • Canada
  • October 27 2016

The respondent Mr. Li established the companies in question in 2007 with Ming Li. He owned 58 of the capital stock and Ming Li owned 42. On March


Federal Court of Appeal grants minister of health the right to be wrong
  • Gowling WLG
  • Canada
  • October 24 2016

In a decision dated October 12, 2016, the Federal Court of Appeal upheld two decisions of the minister of health (the “minister”) to issue Notice of


Patent survives anticipation attack based on use in Phase III clinical trial
  • Gowling WLG
  • Canada
  • September 22 2016

On September 7, 2016, the Federal Court found that Apotex and Cobalt infringed three claims of Bayer’s Canadian Letters Patent No. 2,382,426.1 The


Obviousness central to Federal Court’s REYATAZ (atazanavir bisulfate) decision
  • Gowling WLG
  • Canada
  • June 24 2016

In a decision dated May 27, 2016 in respect of Bristol-Myers Squibb’s (“BMS”) REYATAZ (atazanavir bisulfate), Justice Mactavish of the Federal


Janssen awarded damages almost 10 years after Teva found to have infringed LEVAQUIN patent
  • Gowling WLG
  • Canada
  • June 24 2016

In a recent decision of the Federal Court (Janssen Inc. v. Teva Canada Limited, 2016 FC 593), Justice Hughes awarded approximately $18 million in


Post Amazon.com: How the Canadian Patent Appeal Board has dealt with patent-eligibility of computer-implemented subject matter
  • Gowling WLG
  • Canada
  • June 15 2016

Originally published on June 1, 2015 Updated on June 15, 2016 An important consideration for every patentee is that each countries’ patent system has